Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy

被引：22

作者：

Clarke, S ^{[1
]}

Harrington, P ^{[1
]}

Condon, C ^{[1
]}

Kelleher, D ^{[1
]}

Smith, OP ^{[1
]}

Mulcahy, F ^{[1
]}

机构：

[1] St James Hosp, Dept Genitourinary Med, Dublin 8, Ireland

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 2000年 / 11卷 / 05期

关键词：

nevirapine; hepatitis; HIV; antiretroviral therapy;

D O I：

10.1258/0956462001915831

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The aetiology of hepatic dysfunction in patients with PIN infection is multifactorial. Re-activation of hepatitis C infection, drug toxicity, and opportunistic infections are all potential causes. Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for the treatment of HN infection. It is associated with a significant incidence of hepatotoxicity, usually occurring in the initial month of therapy. We report the case of a 49-year-old man who developed NVP-induced prolonged hepatotoxicity 5 months after commencing antiretroviral therapy.

引用

页码：336 / 337

页数：2

共 5 条

[1] A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients [J].

Carr, A ;

Vella, S ;

deJong, MD ;

Sorice, F ;

Imrie, A ;

Boucher, CA ;

Cooper, DA .

AIDS, 1996, 10 (06) :635-641

[2] Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - A randomized, double-blind, placebo-controlled trial [J].

DAquila, RT ;

Hughes, MD ;

Johnson, VA ;

Fischl, MA ;

Sommadossi, JP ;

Liou, SH ;

Timpone, J ;

Myers, M ;

Basgoz, N ;

Niu, M ;

Hirsch, MS ;

Costanzo, L ;

Ruben, S ;

Berzins, B ;

Martinez, A ;

Fishman, I ;

Kazial, K ;

Cort, SN ;

Robinson, P ;

Hall, D ;

Macy, H ;

McLaren, C ;

Rooney, J ;

Warwick, J ;

CavailleColl, M ;

Valentine, F ;

Booth, D ;

Soeiro, R ;

Stein, D ;

Zingman, B ;

Schliosberg, J ;

Polsky, B ;

Sepkowitz, K ;

Sharpe, V ;

Giordano, M ;

Wanke, C ;

Gulick, R ;

Craven, D ;

Grodman, C ;

Fife, K ;

Black, J ;

Todd, K ;

Nixon, H ;

Sperber, K ;

Gerits, P ;

Mildvan, D ;

Nicholas, P ;

Murphy, RL ;

Kessler, H ;

Pulvirenti, J .

ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1019-1030

[3] HIGH-DOSE NEVIRAPINE - SAFETY, PHARMACOKINETICS, AND ANTIVIRAL EFFECT IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].

HAVLIR, D ;

CHEESEMAN, SH ;

MCLAUGHLIN, M ;

MURPHY, R ;

ERICE, A ;

SPECTOR, SA ;

GREENOUGH, TC ;

SULLIVAN, JL ;

HALL, D ;

MYERS, M ;

LAMSON, M ;

RICHMAN, DD .

JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :537-545

[4] A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients - The INCAS trial [J].

Montaner, JSG ;

Reiss, P ;

Cooper, D ;

Vella, S ;

Harris, M ;

Conway, B ;

Wainberg, MA ;

Smith, D ;

Robinson, P ;

Hall, D ;

Myers, M ;

Lange, JMA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (12) :930-937

[5]

SKOWRON G, 1999, 6 C RETR OPP INF CHI

← 1 →